Today's Rundown Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug Sanofi axes cancer combo, early next-gen diabetes drug Andreessen Horowitz leads $75M round for Tmunity as it eyes phase 2 studies for 2021 [Sponsored] RenMab™ Mouse: a leading platform for fully human antibody generation Astellas, Pandion team up on Type 1 diabetes bispecifics in deal worth up to $795M Ex-Pfizer team leads Pinteon into phase 1 Alzheimer's trial Medtronic launches brain-stim programmer on a Samsung phone Featured Story | | | Thursday, October 31, 2019 Roche is paying Dicerna Pharmaceuticals $200 million (€179 million) upfront for a global license to phase 1 hepatitis B prospect DCR-HBVS. The deal, which will see Roche and Dicerna collaborate on other hepatitis B virus assets, is worth up to $1.5 billion in milestones. |
|
|---|
|
| | White Paper: Rise in Targeted Therapies Biologics have experienced steady double-digit growth over the last 15 years. Precision medicine is also on the rise. Learn more about what to look for when navigating this new era of small-volume manufacturing. |
Top Stories Thursday, October 31, 2019 If you’ve been paying attention this week, you’ve seen that nearly every Big Pharma has been sweeping out dead R&D projects: Sanofi, posting its third-quarter results early this morning, is no different. Thursday, October 31, 2019 In January, Tmunity Therapeutics laid out an “aggressive” plan to unveil new targets, move programs into the clinic and boost its headcount. As it delivers on some of those goals, the cell therapy biotech is coming back to the well for a $75 million series B that will take it into phase 2 studies in 2021. Monday, October 28, 2019 Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts, authentic position within the chromosome. Wednesday, October 30, 2019 As Pandion Therapeutics preps its lead program for the clinic, the autoimmune specialist is giving its earlier-stage pipeline a boost. It is teaming up with Astellas Pharma to discover, develop and market bispecific drugs for Type 1 diabetes and other autoimmune diseases of the pancreas in a deal that could total nearly $800 million. Thursday, October 31, 2019 Pinteon Therapeutics has begun a phase 1 trial of an anti-tau treatment for Alzheimer’s disease. Led by ex-Pfizer scientists, Pinteon is using $17 million in series A funding to assess the safety, tolerability and pharmacokinetics of lead asset PNT001. Wednesday, October 30, 2019 Medtronic has launched a new system that allows patients to manage their deep brain stimulation treatments at home using a dedicated and customized Samsung smartphone. | | QUALITY. SPEED. VALUE.
You Can Have All Three We deliver potent, picomolar-affinity, development-ready human antibodies in a greater number and a shorter timeline than other CROs using transgenic animals, in vitro display or humanization, including for difficult targets such a GPCRs. Contact us at info@alivamab.com to learn more. alivamab.com |
Resources Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 